Phase 3 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to sign a written consent form agreeing to take part in the study.
• Women aged 18 to 70 years old.
• People who have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue or cell sample.
• People whose cancer has stopped responding to platinum-based chemotherapy — either during or very soon after their first course of treatment, or within 6 months of their last platinum-based treatment — and who have had no more than one treatment course for returning disease.
• People whose cancer has been shown to be growing on a recent scan during their last treatment.
• People who are generally well enough to carry out light activity and care for themselves (based on a standard medical fitness scale, scored 0 or 1).
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
• People whose blood test results meet certain minimum levels for red blood cells, white blood cells, and platelets (confirm specific values with trial site).
• People whose liver and kidney function blood tests fall within acceptable ranges (confirm specific values with trial site).
• People whose blood clotting test results fall within acceptable ranges (confirm specific values with trial site).
• People who are expected to live for at least 3 more months.

Who may not be able to join:

• People who have previously been treated with certain drugs that target blood vessel growth (such as Bevacizumab, Apatinib, Anlotinib, or similar), or drugs called Aurora kinase inhibitors.
• People who have previously received weekly paclitaxel chemotherapy.
• People with known allergies to the study drugs (Chiauranib or paclitaxel) or any of their ingredients.
• People who have had biological therapy, immunotherapy, or hormonal therapy within the 28 days before starting the study.
• People who had major surgery or a significant injury within the 14 days before starting the study, or who have a wound, fracture, or ulcer that has not healed.
• People who have taken part in another clinical trial or used an experimental treatment or device within 28 days before starting the study.
• People who still have side effects from a previous cancer treatment that are more than mild in severity.
• People who have had another type of invasive cancer in the past 5 years, except for certain treated skin cancers or cervical cancer in its earliest stage.
• People with a history of cancer that has spread to the brain or the lining of the brain or spinal cord.
• People with significant disease affecting the brain or nerves.
• People with serious or uncontrolled heart conditions, including heart failure, unstable chest pain, a heart attack within the past 6 months, certain irregular heart rhythms, low heart pumping function, certain inherited heart muscle diseases, a history of abnormal heart electrical readings, coronary heart disease requiring medication, or high blood pressure that has needed two or more medications to control or remains above 140/90 mmHg.
• People who have had a serious blood clot event — such as a stroke, pulmonary embolism, or untreated deep vein thrombosis — within the past 6 months.
• People who have had active bleeding in the past 2 months, who have a condition that may cause bleeding, or who are currently taking blood-thinning medication.
• People whose chest scan shows lung inflammation, scarring, or a lung condition requiring treatment, or who have had pneumonia in the past 6 months needing steroid treatment, or who have had immune-related lung inflammation after receiving certain immunotherapy drugs.
• People with significant digestive system problems that could affect how oral medication is absorbed, a history of a hole or abnormal opening in the digestive tract, a stomach ulcer within the past 6 months, or a bowel blockage within the past 3 months.
• People who have significant or symptomatic fluid build-up around the lungs, in the abdomen, or around the heart that has needed draining, or who had such fluid drained within 1 month before starting the study.
• People who test positive for HIV.
• People who test positive for active Hepatitis B or Hepatitis C infections with evidence of the virus actively replicating.
• People with an active infection requiring antibiotic or antifungal treatment by mouth or through a drip at the time of screening.
• People with a mental health or cognitive condition that would affect their ability to understand the consent form or follow the study requirements.
• People who have had an organ transplant or a bone marrow/stem cell transplant from a donor.
• People with current drug or alcohol misuse problems.
• Women who are pregnant or breastfeeding, or women of childbearing potential who are not willing to use adequate contraception for the duration of the study.
• People who have any other condition that the trial doctors consider makes participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.